Download PDF 53 scenar therapy effectiveness in uterus myoma

Start Download Now
Download Download Myoma Ebook

SCENAR-THERAPY EFFECTIVENESS IN UTERUS MYOMA


Uterus myoma is a rather widespread disease. The literature says that 15-17%
of women over 30 have the myoma (V.I. Kulakov and co-authors, 1995). Uterus
myoma is a non-malignant growth of muscular and connective elements. In modern
science uterus myoma is considered as a dyshormonal tumor with violations in the
system hypothalamus – hypophisis – adrenal cortex – ovary. Tumor’s dyshormonal
nature causes some metabolic disorders, functional liver deficiency and often disoders
in adipose metabolism. Hypothalamus-hypophisis disorders may precede the
appearance of a neoplasm or develop secondarily from the myomatic uterus due to
pathologic afferentation.
Patients with uterus myoma often have violations of menstrual function, pain
syndrome and sterility.
Searching for new effective methods of treating uterus myoma is a current
problem of today’s medicine.
There are only several reports on using SCENAR-therapy in treating uterus
myoma in literature (L.M. Kudaeva, I.A. Minenko, 1998; G.V. Subbotina, 1997).
The aim of this work is to evaluate the effectiveness of SCENAR-influence in
women with uterus myoma.
The testing group included 12 women from 34 to 45 years old with uterus
fibromyomas. All patients preserved a menstrual function. The diagnosis of uterus
myoma was confirmed by USI in 100% of cases.
All USI investigations were done on the 8-10 day of the menstrual cycle.
Clinical investigations showed the predominance of hyperpolimenorhea (11
women or 91.6%), aches in the bottom of the stomach (9 or 75%), dysuria disorders
(7 or 58.3%), violations of bowel function – constipations (8 or 66.6%), blood secretion
between menstruation periods (6 or 50%), easy fatigability (10 or 83%), sterility (5 or
41.6%).
Treatment results were estimated basing on changes in female subjective
sensations, USI data, and in some cases basing on results of histological investigation
of endometritis taken by scraping off the uterus cavity.
The patients underwent SCENAR electropulse therapy according to the long
scheme (3-6 courses with 20 sessions during the first menstrual cycle and 7 sessions
during the second menstrual cycle) or according to the short scheme (7 days before the
menstruation and 7 days after it).



The zones of common influence were stimulated (along the barbate outgrowths;
two paravertebral lines at the electrode width distance from the backbone; six points –
trifacial’s output on the face, three on each side; neck-collar zone) and local zones
(sacral-backbone, suprapubic, liver, spleen, adrenals and others). Kidneys’, liver’s,
adrenals’ and pancreas’s meridians were also stimulated. The treatment was made in
constant and individually dosed modes considering signs of small asymmetry. Sessions
were made daily, 20-40 minutes each.
After the SCENAR-therapy course 7 patients had normal uterus size, 5 women
had considerably decreased uterus size corresponding to the 5th-6th week of pregnancy.
All supervised had regress of clinical symptomatology (decreased hyperpolymenorhea,
pain syndrome, dysuria disorders and so on).
It is worth mentioning that on the first stage of treatment in some women uterus
myoma increased to a certain extent, but later considerably decreased. So it was
necessary to do USI in 1-2 months after electropulse therapy.
Apparently, SCENAR-stimulation activates interrelations between central nervous
system, immune and endocrine systems and it contributes to normalization of
homeostatic indices. Mechanism of their influence is connected with activating
adaptation-compensatory processes with gradual increase of functional reserves in the
process of individually oriented course influence, as well as with non-specific body
protection in general (V.G. Zilov with co-authors, 2000).
The above-mentioned mechanism of SCENAR-influence contributes to high
healing effect in gynecological pathology and makes it perspective in the obstetricians’
and gynecologists’ practice.
Here is an example of two cases of uterus myoma disease.
A 43-year-old patient had been under observation because of this pathology for
6 years.
At her coming USI showed a multiple uterus myoma equal to 13-14 weeks of
pregnancy. The woman was suggested to be operated on, but rejected it out of hand
and decided to undergo SCENAR-therapy.
After the first course of treatment the myoma’s size decreased and equaled 9
weeks of pregnancy. After the second course of treatment neoformation’s size went on
decreasing and was equal to 7-8 weeks of pregnancy. USI made in the end of the third
course diagnosed the myoma equal to 6 weeks of pregnancy. After four courses of
SCENAR-therapy the uterus took its normal size, there was only one node 15 mm in
diameter. The patient felt better after the first course of treatment, hemoglobin was
almost normal (112 g/w.b.c.), there weren’t any dysuric disorders, and menstrual cycle
was restored.
The second patient was 40 years old and had submucous uterus myoma
complicated by hyperpolimenorhea.
The woman had polyvalent drug allergy. In this situation the patient underwent
SCENAR-therapy from the last day of the previous menstruation till the first day of the
current menstruation with the pause for menstruation and 7-day treatment more after
the menstruation.
After the second course of SCENAR-therapy (during the second phase of
menstruation cycle) there was a spontaneous formation of myomatous node 30 mm in
diameter. Repeated USI didn’t indicate any nodes. Menstruation cycle was restored,
pains ended.


Research results show the importance of SCENAR-therapy in treating
gynecological pathology as it is quite simple in use, highly effective and produces
steady positive effect. It is necessary to continue further research on this problem.